Blueprint Medicines Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Blueprint Medicines Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass., May 6, 2024 /PRNewswire/ -- Blueprint Medicines Corporation (Nasdaq: BPMC), today announced that, effective May 1, 2024, the Compensation Committee of Blueprint Medicines' Board of Directors granted non-qualified stock options to purchase an aggregate of 6,400 shares of its common stock and an aggregate of 3,200 restricted stock units (RSUs) to two new employees under Blueprint Medicines' 2020 Inducement Plan.
馬薩諸塞州劍橋，2024年5月6日 /PRNewswire/ — Blueprint Medicines Corporation（納斯達克股票代碼：BPMC）今天宣佈，根據Blueprint Medicines的2020年激勵計劃，藍圖醫藥董事會薪酬委員會向兩名新員工授予了總共6,400股普通股和總共3,200個限制性股票單位（RSU）的非合格股票期權。
The 2020 Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously an employee or non-employee director of Blueprint Medicines, as an inducement material to such individual's entering into employment with Blueprint Medicines, pursuant to Rule 5635(c)(4) of the Nasdaq Listing Rules.
根據納斯達克上市規則第5635（c）（4）條，2020年激勵計劃專門用於向以前不是Blueprint Medicines僱員或非僱員董事的個人發放股權獎勵，以此作爲此類個人在Blueprint Medicines工作的激勵材料。
The options have an exercise price of $94.86 per share, which is equal to the closing price of Blueprint Medicines' common stock on May 1, 2024. Each option will vest as to 25% of the shares underlying such option on the first anniversary of the grant date and as to an additional 1/48th of the shares underlying the option monthly thereafter, in each case, subject to each such employee's continued employment on each vesting date. Each RSU will vest as to 25% of the shares underlying the RSU award on the first anniversary of the grant date and as to an additional 25% of the shares underlying the RSU award annually thereafter, subject to each such employee's continued employment on each vesting date. The options and RSUs are subject to the terms and conditions of Blueprint Medicines' 2020 Inducement Plan, and the terms and conditions of the stock option and RSU agreement covering the grant.
這些期權的行使價爲每股94.86美元，等於2024年5月1日Blueprint Medicines普通股的收盤價。在每種情況下，每種期權將在授予日一週年之際授予該期權標的股份的25％，此後每月再授予該期權所依據股份的1/48％，前提是每位此類員工在每個歸屬日的持續工作。每個 RSU 將在授予日一週年之際授予 RSU 獎勵所依據股份的 25%，此後每年再授予 RSU 獎勵所依據股份的 25%，但須視每位員工在每個歸屬日的持續就業情況而定。期權和限制性股票單位受Blueprint Medicines2020年激勵計劃的條款和條件以及涵蓋該補助金的股票期權和RSU協議的條款和條件的約束。
About Blueprint Medicines
關於《藍圖藥品》
Blueprint Medicines is a global, fully integrated biopharmaceutical company that invents life-changing medicines. We seek to alleviate human suffering by solving important medical problems in two core focus areas: allergy/inflammation and oncology/hematology. Our approach begins by targeting the root causes of disease, using deep scientific knowledge in our core focus areas and drug discovery expertise across multiple therapeutic modalities. We have a track record of success with two approved medicines, including AYVAKIT/AYVAKYT (avapritinib), which we are bringing to patients with systemic mastocytosis (SM) in the U.S. and Europe. Leveraging our established research, development, and commercial capability and infrastructure, we now aim to significantly scale our impact by advancing a broad pipeline of programs ranging from early science to advanced clinical trials in mast cell diseases including SM and chronic urticaria, breast cancer and other solid tumors. For more information, visit and follow us on X (formerly Twitter; @BlueprintMeds) and LinkedIn.
Blueprint Medicines是一家全球性、完全整合的生物製藥公司，致力於發明改變生活的藥物。我們尋求通過解決兩個核心重點領域的重要醫療問題來減輕人類痛苦：過敏/炎症和腫瘤學/血液學。我們的方法首先是針對疾病的根本原因，運用我們核心重點領域的深厚科學知識和跨多種治療模式的藥物研發專業知識。我們有兩種獲批藥物的成功記錄，其中包括AYVAKIT/AYVAKYT（阿伐替尼），我們正在爲美國和歐洲的系統性肥大細胞增多症（SM）患者提供這種藥物。利用我們既有的研究、開發、商業能力和基礎設施，我們現在的目標是通過推進一系列廣泛的項目，從早期科學到高級臨床試驗，包括SM和慢性蕁麻疹、乳腺癌和其他實體瘤的肥大細胞疾病，來顯著擴大我們的影響力。欲了解更多信息，請在 X（前身爲 Twitter；@BlueprintMeds）和 LinkedIn 上訪問並關注我們。
SOURCE Blueprint Medicines Corporation
來源 Blueprint
譯文內容由第三人軟體翻譯。